Funding oncology clinical trials: Are cooperative group trials sustainable?

Journal of Clinical Oncology

Volumn 30, Issue 13, 2012, Pages 1456-1461

  Seow, Hsien Yeang ^a,b,c   Whelan, Patrick ^b   Levine, Mark N ^a,b,c   Cowan, Kathryn ^b   Lysakowski, Barbara ^b   Kowaleski, Brenda ^b   Snider, Anne ^b,c   Xu, Rebecca Y ^b   Arnold, Andrew ^b,c  

^a MCMASTER UNIVERSITY   (Canada)

^b JURAVINSKI CANCER CENTRE   (Canada)

^c Escarpment Cancer Research Institute   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BUDGET; CANCER CENTER; CANCER RESEARCH; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; COST; FUNDING; HEALTH CARE ORGANIZATION; HUMAN; INCOME; PRIORITY JOURNAL; CANADA; COOPERATION; ECONOMICS; FINANCIAL MANAGEMENT; HEALTH CARE COST; METHODOLOGY; NEOPLASM; ORGANIZATION AND MANAGEMENT; RETROSPECTIVE STUDY; STATISTICAL MODEL; TIME; TREATMENT OUTCOME; UNIVERSITY HOSPITAL;

ACADEMIC MEDICAL CENTERS; CANADA; CANCER CARE FACILITIES; CLINICAL TRIALS AS TOPIC; COOPERATIVE BEHAVIOR; HEALTH CARE COSTS; HEALTH CARE SECTOR; HEALTH EXPENDITURES; HUMANS; INCOME; MODELS, ECONOMIC; NEOPLASMS; RESEARCH DESIGN; RESEARCH SUPPORT AS TOPIC; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84863009650     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.37.2698     Document Type: Article

References (16)

1. Institute of Medicine. A National Cancer Clinical Trials System for the 21st Century: Reinvigorating The NCI Cooperative Group Program. Washington, DC: The National Academies Press, 2010
2. Faltering cancer trials. New York Times, April 25, 2010:WK11. http://www.nytimes.com/2010/04/25/opinion/25sun1.html
3. Young RC: Cancer clinical trials: A chronic but curable crisis. N Engl J Med 363:306-309, 2010
4. Dilts DM, Sandler AB, Cheng SK, et al: Steps and time to process clinical trials at the Cancer Therapy Evaluation Program. J Clin Oncol 27:1761-1766, 2009
5. Minasian LM, O'Mara AM. Accrual to clinical trials: Let's look at the physicians. J Natl Cancer Inst 103:357-358, 2011
6. Sargent DJ, George SL: Clinical trials data collection: When less is more. J Clin Oncol 28:5019-5021, 2010
7. Kaiser LD, Melemed AS, Preston AJ, et al: Optimizing collection of adverse event data in cancer clinical trials supporting supplemental indications. J Clin Oncol 28:5046-5053, 2010
8. Roche K, Paul N, Smuck B, et al: Factors affecting workload of cancer clinical trials: Results of a multicenter study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 20:545-556, 2002 (Pubitemid 34081107)
9. Goodwin PJ, Stambolic V, Lemieux J, et al: Evaluation of metformin in early breast cancer: A modification of the traditional paradigm for clinical testing of anti-cancer agents. Breast Cancer Res Treat 126:215-220, 2011
10. Ebel W, Routhier EL, Foley B, et al: Preclinical evaluation of MORAb-003, a humanized monoclonal antibody antagonizing folate receptor-alpha. Cancer Immun 7:6, 2007
11. Kalli KR: MORAb-003, a fully humanized monoclonal antibody against the folate receptor alpha, for the potential treatment of epithelial ovarian cancer. Curr Opin Investig Drugs 8:1067-1073, 2007
12. U.S. Securities and Exchange Commission: Ponzi Schemes-Frequently Asked Questions. http://www.sec.gov/answers/ponzi.htm
13. Rehnquist J. The Globalization of Clinical Trials: A Growing Challenge in Protecting Human Subjects. Department of Health and Human Services, Office of Inspector General, September 2001. http://oig.hhs.gov/oei/reports/oei-01-00- 00190.pdf
14. Shah S: Globalization of clinical research by the pharmaceutical industry. Int J Health Serv 33:29-36, 2003
15. Olliaro PL, Vijayan R, Inbasegaran K, et al: Drug studies in developing countries. Bull World Health Organ 79:894-895, 2001 (Pubitemid 32896115)
16. Wright JR, Roche K, Smuck B, et al: Estimating per patient funding for cancer clinical trials: An Ontario based survey. Contemp Clin Trials 26:421-429, 2005 (Pubitemid 41073671)